Intoplicine (dimesylate)

Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (KA = 2 x 105 /M) and thereby increases the length of linear DNA[1][2].

Product Specifications

CAS Number

[133711-99-6]

Product Name Alternative

RP 60475 (dimesylate)

UNSPSC

12352005

Target

Topoisomerase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/intoplicine-dimesylate.html

Concentration

10mM

Purity

98.28

Solubility

DMSO : 115 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

OC1=CC=C2C3=C(NC4=C3C(NCCCN(C)C)=NC=C4C)C=CC2=C1.CS(O)(=O)=O.CS(O)(=O)=O

Molecular Formula

C23H32N4O7S2

Molecular Weight

540.65

References & Citations

[1]Riou JF, et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 1993;53 (24) :5987-5993.|[2]Eckardt JR, et al. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst. 1994;86 (1) :30-33.|[3]Bissery MC, et al. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice. Invest New Drugs. 1993;11 (4) :263-277.